BRPI0210317C1 - complexo de vacina terapêutica destinado à prevenção ou ao tratamento de leishmanioses e infecções mediadas por microorganismos patogênicos intracelulares nos mamíferos - Google Patents

complexo de vacina terapêutica destinado à prevenção ou ao tratamento de leishmanioses e infecções mediadas por microorganismos patogênicos intracelulares nos mamíferos

Info

Publication number
BRPI0210317C1
BRPI0210317C1 BRPI0210317A BR0210317A BRPI0210317C1 BR PI0210317 C1 BRPI0210317 C1 BR PI0210317C1 BR PI0210317 A BRPI0210317 A BR PI0210317A BR 0210317 A BR0210317 A BR 0210317A BR PI0210317 C1 BRPI0210317 C1 BR PI0210317C1
Authority
BR
Brazil
Prior art keywords
leishmaniasis
mammals
prevention
treatment
pathogenic microorganisms
Prior art date
Application number
BRPI0210317A
Other languages
English (en)
Other versions
BRPI0210317B1 (pt
BRPI0210317B8 (pt
BR0210317A (pt
Inventor
Papierok Gérard
Lemesre Jean-Loup
Vicens Serge
Original Assignee
Bio Veto Tests Abreviadamente Bvt Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Veto Tests Abreviadamente Bvt Sarl filed Critical Bio Veto Tests Abreviadamente Bvt Sarl
Publication of BR0210317A publication Critical patent/BR0210317A/pt
Publication of BRPI0210317B1 publication Critical patent/BRPI0210317B1/pt
Publication of BRPI0210317B8 publication Critical patent/BRPI0210317B8/pt
Publication of BRPI0210317C1 publication Critical patent/BRPI0210317C1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/002Protozoa antigens
    • A61K39/008Leishmania antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fodder In General (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

complexo de vacina terapêutica destinado à prevenção ou ao tratamento de leishmanioses e infecções mediadas por microorganismos patogênicos intracelulares nos mamíferos complexo de vacina terapêutica destinado à prevenção ou ao tratamento de leishmanioses e infecções mediadas por microorganismos patogênicos intracelulares nos mamíferos e em particular no homem, nos caninos, nos felinos e nos eqüídeos, caracterizado pelo fato de que ele é composto por moléculas de excreção secreção provenientes de promastigotos de leishmania sp. produzidos em um meio sem germes e sem soro definido.
BRPI0210317A 2001-06-11 2002-05-30 complexo de vacina terapêutica destinado à prevenção ou ao tratamento de leishmanioses e infecções mediadas por microorganismos patogênicos intracelulares nos mamíferos BRPI0210317C1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0107606A FR2825633B1 (fr) 2001-06-11 2001-06-11 Complexe vaccinal therapeutique destine a la prevention et au traitement des leishmanioses et des infections a microorganismes pathogenes intracellulaires chez le mammifere
PCT/FR2002/001823 WO2002100430A1 (fr) 2001-06-11 2002-05-30 Complexe vaccinal destine a la prevention et au traitement des leishmanioses

Publications (4)

Publication Number Publication Date
BR0210317A BR0210317A (pt) 2004-08-10
BRPI0210317B1 BRPI0210317B1 (pt) 2018-09-11
BRPI0210317B8 BRPI0210317B8 (pt) 2018-10-09
BRPI0210317C1 true BRPI0210317C1 (pt) 2021-05-25

Family

ID=8864170

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0210317A BRPI0210317C1 (pt) 2001-06-11 2002-05-30 complexo de vacina terapêutica destinado à prevenção ou ao tratamento de leishmanioses e infecções mediadas por microorganismos patogênicos intracelulares nos mamíferos

Country Status (10)

Country Link
US (1) US20060073170A1 (pt)
EP (1) EP1395282B1 (pt)
AT (1) ATE321568T1 (pt)
BR (1) BRPI0210317C1 (pt)
CY (1) CY1105309T1 (pt)
DE (1) DE60210276T2 (pt)
ES (1) ES2260440T3 (pt)
FR (1) FR2825633B1 (pt)
PT (1) PT1395282E (pt)
WO (1) WO2002100430A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8968749B2 (en) * 2006-07-21 2015-03-03 Universidade Federal De Minas Gerais—Ufmg Vaccine composition and immunization method
EP2288379A4 (en) 2008-05-19 2012-08-08 Advaxis DOUBLE RELEASE SYSTEM FOR HETEROLOGIST ANTIGENE
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
PT2566506T (pt) * 2010-05-07 2016-10-12 Virbac Composição de vacina para a prevenção ou tratamento de leishmanioses
WO2012138377A2 (en) * 2010-10-01 2012-10-11 Trustees Of The University Of Pennsylvania The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
AU2013232291B8 (en) 2012-03-12 2016-07-21 Advaxis, Inc. Suppressor cell function inhibition following listeria vaccine treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206252A (en) * 1977-04-04 1980-06-03 Gordon Roy G Deposition method for coating glass and the like
US5599387A (en) * 1993-02-16 1997-02-04 Ppg Industries, Inc. Compounds and compositions for coating glass with silicon oxide
FR2705358B1 (fr) * 1993-05-13 1995-08-04 Orstom Procédé de culture in vitro de différents stades de parasites tissulaires, stades parasitaires obtenus et applications biologiques.
WO2000015572A2 (en) * 1998-09-17 2000-03-23 Libbey-Owens-Ford Co. Heat strengthened coated glass article and method for making same
US6342925B1 (en) * 1999-01-15 2002-01-29 Sharp Laboratories Of America, Inc. Automatic audio and video parameter adjustment
US7738550B2 (en) * 2000-03-13 2010-06-15 Sony Corporation Method and apparatus for generating compact transcoding hints metadata
BRPI0114262B1 (pt) * 2000-09-27 2018-09-25 Thomson Licensing Sa sistema para otimização automática dos modos de saída de áudio e vídeo para saída de um dispositivo multimídia
US6967588B2 (en) * 2002-03-25 2005-11-22 Sony Corporation System and method for controlling a home entertainment system

Also Published As

Publication number Publication date
EP1395282A1 (fr) 2004-03-10
FR2825633A1 (fr) 2002-12-13
WO2002100430B1 (fr) 2003-02-13
ES2260440T3 (es) 2006-11-01
US20060073170A1 (en) 2006-04-06
FR2825633B1 (fr) 2005-12-16
BRPI0210317B1 (pt) 2018-09-11
CY1105309T1 (el) 2010-03-03
ATE321568T1 (de) 2006-04-15
PT1395282E (pt) 2006-07-31
BRPI0210317B8 (pt) 2018-10-09
BR0210317A (pt) 2004-08-10
DE60210276D1 (de) 2006-05-18
EP1395282B1 (fr) 2006-03-29
WO2002100430A1 (fr) 2002-12-19
DE60210276T2 (de) 2006-11-30

Similar Documents

Publication Publication Date Title
HRP20020593B1 (en) Brain, spinal and nerve injury treatment
GB0108592D0 (en) Therapeutic agents
BRPI0415397A (pt) métodos e reagentes para o tratamento de desordens imunoinflamatórias
BR0213358A (pt) Uso de flibanserina
WO2001045679A3 (de) Verwendung von chemotherapeutika zur topischen behandlung
BR9913225A (pt) Novos agentes antibacterianos de isoxazolinona
BR0213100A (pt) Combinações para o tratamento de distúrbios imuniinflamatórios
BR0111892A (pt) Bis-arilsulfonas
ATE319439T1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
BRPI0210317C1 (pt) complexo de vacina terapêutica destinado à prevenção ou ao tratamento de leishmanioses e infecções mediadas por microorganismos patogênicos intracelulares nos mamíferos
AU6896801A (en) Use of vegf and homologues to treat neuron disorders
RS8504A (en) Novel cyclohexil sulphones
ATE258057T1 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
BR0211830A (pt) Dose única de azitromicina
BR0214060A (pt) Uso de monoidroxicarbamazepina em distúrbio afetivo e de atenção e dor neuropática
HUP0003845A2 (hu) Antimikrobiális 8a-azalidok alkalmazása
BR0309684A (pt) O tratamento de dor com ifendropil
GB2377638B (en) Treatment of infection in animals
ATE341323T1 (de) Verwendung von darifenacin zur behandlung des harndrangs
DK1235573T3 (da) Kombination af riluzol og gabapentin og anvendelse deraf som medikament ved behandling af motorneuronsygdomme
AU2001276323A1 (en) Use of n-oleoylethanolamine for treating psoriasis
BRPI0411731A (pt) tratamento de enxaqueca acompanhada por náusea
ES2166912T3 (es) Composiciones, que comprenden bismuto y uno o mas agentes antimicrobianos, para el tratamiento y prevencion de trastornos gastrointestinales.
PT1282414E (pt) Compostos derivados de felbamato para o tratamento da dor neuropatica
BR0007491A (pt) Uso de 3-isoxazolidinonas e ácidos hidroxilâmicospara o tratamento de infecções

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/09/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/09/2018, OBSERVADAS AS CONDICOES LEGAIS. (CO) REFERENTE A RPI 2488 DE 11/09/2018, QUANTO AO NOME DO TITULAR.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/05/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2725 DE 28/03/2023 POR TER SIDO INDEVIDA, UMA VEZ QUE O PRAZO DE VALIDADE DA PATENTE TERMINOU EM 30/05/2022.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 30/05/2022